In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection. In this study, we aim to evaluate the virological and clinical outcomes of subjects following a contact at high/moderate risk of SARS-CoV-2 acquisition, in community-subjects and/or healthcare workers. The study population is represented by all subjects who had a contact with laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at high/moderate risk of SARS-CoV-2 acquisition. This include both children and adult subjects, subject without social security, and healthcare workers.
Procedures added by the research: Blood sampling for determination of the presence of SARS-CoV-2 type M immunoglobulins or type G immunoglobulins. Blood sampling for whole exome sequencing
Study Type
OBSERVATIONAL
Enrollment
81
SARS-CoV-2 serology
Whole exome sequencing
Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon
Besançon, France
Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin
Bordeaux, France
Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand
Clermont-Ferrand, France
Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne
Dijon, France
Centre d'investigation clinique 1406 CHU Grenoble
Grenoble, France
Centre d'Investigation Clinique 1403 -CHU Lille
Lille, France
Centre d'Investigation Clinique Hôpital Saint Louis
Paris, France
Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard
Paris, France
Hôpital Cochin CIC 1417 Bâtiment Lavoisier
Paris, France
Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou
Rennes, France
...and 6 more locations
Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.
Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay
Time frame: 30 days (+/-7)
Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7);
Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay
Time frame: 30 days (+/-7)
Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.
ELISA, microneutralisation assay
Time frame: 365 days (+/-30)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.